Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics and keeping the price target at $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Tenaya Therapeutics’ recent financial and clinical developments. The company reported a better-than-expected EPS for the second quarter of 2025, alongside a solid cash position of $71.7 million, which is projected to support operations through the second half of 2026. This financial stability is complemented by significant progress in their gene therapy programs, particularly in cardiovascular applications.
Tenaya’s advancements in clinical trials, such as the MyPEAK-1 and RIDGE-1 trials, have shown promising safety profiles, allowing for dose expansion in their ongoing studies. The completion of patient enrollment in key cohorts and the anticipation of data readouts in the fourth quarter of 2025 further bolster confidence in the company’s potential. These clinical milestones, coupled with the company’s strategic financial management, underpin Pantginis’s optimistic outlook on Tenaya’s stock, leading to the Buy rating.